Patrick W. Serruys1*, MD, PhD; Yosuke Miyazaki2, MD, PhD; Athanasios Katsikis3, MD, PhD; Mohammad Abdelghani4, MD; Martin B. Leon5, MD; Renu Virmani6, MD; Thierry Carrel7, MD; Martijn Cox8, PhD; Yoshinobu Onuma2,9, MD, PhD; Osama I.I. Soliman2,9, MD, PhD
1. Imperial College London, London, United Kingdom; 2. Department of Cardiology, Thoraxcenter, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands; 3. Cardiology Department, 401 General Military Hospital of Athens, Athens, Greece; 4. Department o
The current standard of treatment of valvular diseases with severe functional and/or clinical consequences is the repair or replacement of the valve, which is usually surgical or, in specific scenarios, percutaneous. The avai
